Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Resverlogix Corp (RVXCF)

Resverlogix Corp (RVXCF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Resverlogix Appoints Bradley Glass to Board of Directors

Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Company") today announces the appointment of Mr. Bradley Glass, J.D. as a member of the Company's...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders

Calgary, Alberta--(Newsfile Corp. - June 30, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta....

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024

Numerous GLP-1 RA and SGLT2i presentations touted their clinical results, providing continued excitement for our BETonMACE program, which observed a non-prespecified 63% reduction in MACE and heart failure...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension

Calgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual & Special Meeting of Shareholders (the "Meeting") in Calgary,...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges

Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year extension...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Updated Annual and Special Meeting of Shareholders

Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges

Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Change to Its Board of Directors

Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, "The BET inhibitor apabetalone decreases...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Calgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage,...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)

Barchart Exclusives

JPMorgan Says This 1 Chip Stock Is a Strong Buy Now... And It’s Not What You Think It Is
J.P. Morgan upgraded Pepsi, citing expectations for improved performance. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar